Sugi Predict

Sugi Predict / Compounds / SCHEMBL7514367

SCHEMBL7514367

SCHEMBL7514367

CCNc1cc2ncnc(NCc3ccccc3N3CCOCC3)c2cc1[N+](=O)[O-]

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ TDP1 Q9NUW8 2/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ EGFR P00533 2/20 0.47
▸ PDGFRB P09619 1/20 0.46
▸ BRD4 O60885 2/20 0.44
▸ BRD9 Q9H8M2 2/20 0.44
▸ PDE5A O76074 1/20 0.42
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ STAT6 P42226 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ ACHE P22303 1/20 0.40
▸ BACE1 P56817 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7521455 0.92 EGFR (0.48) MAPTALDH1A1EGFRPDGFRBPDE5A
SCHEMBL7530560 0.91 EGFR (0.48) MAPTALDH1A1EGFRPDGFRBPDE5A
SCHEMBL7527697 0.91 EGFR (0.48) MAPTALDH1A1EGFRPDGFRBPDE5A
SCHEMBL7526254 0.91 EGFR (0.48) MAPTALDH1A1EGFRPDGFRBPDE5A
SCHEMBL7527938 0.91 PDGFRB (0.49) L3MBTL1EGFRPDGFRBBRD4BRD9
SCHEMBL7528018 0.90 EGFR (0.47) MAPTALDH1A1EGFRPDGFRBPDE5A
SCHEMBL7527163 0.90 PDGFRB (0.48) MAPTALDH1A1L3MBTL1EGFRPDGFRB
SCHEMBL8796308 0.89 EGFR (0.47) MAPTALDH1A1TDP1L3MBTL1EGFR
SCHEMBL7521565 0.88 PDGFRB (0.47) MAPTALDH1A1L3MBTL1EGFRPDGFRB
SCHEMBL7521285 0.87 PDE5A (0.58) MAPTALDH1A1EGFRPDGFRBPDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0640075-A1 CERTAIN AMINOMETHYL PHENYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1995-03-01 — — EP claimed
WO-1992012134-A2 CERTAIN AMINOMETHYL PHENYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1992-07-23 — — WO claimed
US-20020193389-A1 Method of inhibiting neoplastic cells with imidazoquinazoline derivatives OSI PHARMACEUTICALS, INC. 2002-12-19 — — US disclosed
US-6127541-A 8-((DISUBSTITUTED AMINO)BENZYLAMINO)-2,3-DIHYDRO-1H-IMIDAZO(4,5-G)QUINAZOLINE-(2-THIONE OR 2-ONE); SELECTIVE CYCLIC GUANOSINE 3',5' MONOPHOSPHATE (CGMP)--SPECIFIC PHOSPHODIESTERASE (PDE) INHIBITORY ACTIVITY KYOWA HAKKO KOGYO CO., LTD. (JP) 2000-10-03 — — US disclosed
EP-0863144-A1 IMIDAZOQUINAZOLINE DERIVATIVES Kyowa Hakko Co., Ltd. (JP) 1998-09-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193389-A1 Method of inhibiting neoplastic cells with imidazoquinazoline derivatives MKI67, HRAS, VHL MAPT 4593/4885ALDH1A1 1807/4885TDP1 2540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.